AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function,  to benefit the lives of those patients, their families, and society as a whole. Their science and intellectual property are based on decades of unparalleled research at Johns Hopkins and leading research centers worldwide.